Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026
REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) today announced that the Company will release interim clinical data related to its tagmokitug development program evaluating the cytolytic CCR8 antibody with toripalimab in multiple solid tumors on Wednesday, October 28, 2026. Coherus management will host a webcast from 4:30 p.m. to 6:00 p.m. Eastern Daylight Time to discuss the data and provide additional context. The company has invited key opinion leaders to join the webcast and provide their clinical perspective.
Covered in this story
Call it yourself
No calls on $CHRS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Coherus Oncology Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.